Novel heteroaryl derivatives and their use as medicaments

ABSTRACT

The invention relates to novel acridine derivatives of formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.

BACKGROUND

[0001] The invention relates to novel heteroaryl compounds, methods for their preparation, and to a therapeutic process for their use as medicaments, particularly for treating tumors.

DESCRIPTION OF THE INVENTION

[0002] According to one aspect of the invention, novel acridine derivatives are provided of the formula (1)

[0003] wherein

[0004] R, R₁, R₂, R₃ are attached to any of the acridine carbon atoms C₁₋₉ and are the same or different and independently of one another are hydrogen, hydroxyl, a straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, straight-chain or branched C₁₋₈ alkylcarbonyl, suitably acetyl, straight-chain or branched C₁₋₈ alkoxy, halogen, aryl-C₁₋₈ alkoxy, suitably benzyloxy or phenylethyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, C₁₋₈ alkoxycarbonylamino, C₁₋₆ alkoxycarbonylamino-C₁₋₈ alkyl, cyano, straight-chain or branched cyano-C₁₋₆ alkyl, carboxyl, C₁₋₈ alkoxycarbonyl, C₁₋₄ alkyl which is substituted by one or more fluorine atoms, suitably the trifluoromethyl group, carboxy-C₁₋₈ alkyl or C₁₋₈ alkoxycarbonyl-C₁₋₆ alkyl, C₁₋₆ alkenyl, suitably allyl, C₂₋₆ alkynyl, suitably ethynyl or propargyl, straight-chain or branched cyano-C₁₋₆ alkyl, suitably cyanomethyl, aryl, where the aryl radical is unsubstituted or mono- or polysubstituted by identical or different substituents from the group of halogen, straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, carboxyl, straight-chain or branched C₁₋₈ alkoxycarbonyl, suitably tert-butoxycarbonyl, by trifluoromethyl, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, suitably methoxy or ethoxy, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, cyano, straight-chain or branched cyano-C₁₋₆ alkyl,

[0005] Z is oxygen or sulfur, where the radical

[0006] substituted on the acridine heterocycle is attached to a C atom C₁₋₉ of the acridine ring skeleton;

[0007] P, Q independently of one another represent oxygen or in each case two hydrogen atoms (i.e. —CH₂);

[0008] X is nitrogen or C—R₅, where R₅ is hydrogen or C₁₋₆ alkyl;

[0009] n,m independently of one another denotes a cardinal number between 0 and 3, with the proviso that when n=0, X is a CR₅R₆ group where R₅ and R₆ independently of one another represent hydrogen or C₁₋₆ alkyl and that the nitrogen atom adjacent to the C═Z group is substituted by a hydrogen atom or a C₁₋₆ alkyl group;

[0010] R₄ is a straight-chain or branched C₁₋₂₀ alkyl radical which can be saturated or unsaturated, with one to three double and/or triple bonds, and which can be unsubstituted or substituted at the same or different C atoms by one, two or more aryl, heteroaryl, halogen, cyano, —C═NH (NH₂), C₁₋₆ alkoxycarbonylamino, C₁₋₆ alkoxy, amino, mono-C₁₋₄ alkylamino or di-C₁₋₄ alkylamino; carboxy, C₁₋₄ alkoxycarbonyl; a C₆₋₁₄ aryl radical, C₆₋₁₄ aryl-C₁₋₄ alkyl radical or a C₂₋₁₀ heteroaryl or C₂₋₁₀ heteroaryl-C₁₋₄ alkyl radical which contains one or more heteroatoms that are N, O or S, where the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted with the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and where the C₆₋₁₄ aryl or C₂₋₁₀ heteroaryl radical is unsubstituted or mono- or polysubstituted by the same or different substituents from the group of straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, halogen, cyano, C₁₋₆ alkoxycarbonylamino, C₁₋₆ alkoxy, carboxyl, C₁₋₈ alkoxycarbonyl, straight-chain or branched C₁₋₆ alkyl which is substituted by one or more fluorine atoms, suitably trifluoromethyl, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, suitably methoxy or ethoxy, where adjacent oxygen atoms can also be linked by C₁₋₂ alkylene groups, suitably by a methylene group, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, aryl, which for its part can be unsubstituted or mono- or polysubstituted by identical or different substituents from the group of straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, carboxyl, straight-chain or branched C₁₋₈ alkoxycarbonyl, by trifluoromethyl, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, suitably methoxy or ethoxy, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, cyano, straight-chain or branched cyano-C₁₋₆ alkyl;

[0011] and their structural isomers and stereoisomers, particularly tautomers, diastereomers and enantiomers, and their pharmaceutically acceptable salts, particularly acid addition salts.

[0012] Thus, for example, the compounds of the formula (1) of the present invention which have one or more centers of chirality and which are present as racemates and can be separated by methods known per se into their optical isomers, i.e. enantiomers or diastereomers. The separation can be carried out by column separation on chiral phases or by recrystallization from an optically active solvent or using an optically active acid or base or by derivatization with an optically active reagent, such as, for example, an optically active alcohol, and subsequent removal of the radical.

[0013] Furthermore, the acridine derivatives of the formula (1) of the present invention can be converted into their salts with inorganic or organic acids, especially for pharmaceutical use, into their pharmaceutically acceptable salts. Acids which are suitable for this purpose are, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, acetic acid, tartaric acid, malic acid, malonic acid, embonic acid, trifluoroacetic acid maleic acid, methonesulfuric acid, or sulfo acetic acid.

[0014] Moreover, the compounds of the formula (1) of the invention if desired can be converted if they contain a sufficiently acidic group, such as a carboxyl group, into their salts with inorganic or organic bases, especially for pharmaceutical use, into their pharmaceutically acceptable salts. Bases which are suitable for this purpose are, for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, lysine, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.

[0015] According to a suitable embodiment, acridine derivatives are provided of the formula 1 in which R, R1, R2, R3, X, Z, P, Q, n and m have the meanings given above and

[0016] Y is a substituent group of the same or different substituents of C₁₋₆ alkyl, halogen, nitro, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, hydroxyl, C₁₋₆ alkoxy, benzyloxy, carboxyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxycarbonylamino or C₁₋₆ alkyl mono- or polysubstituted with fluorine, suitably trifluoromethyl, C₁₋₆ aryl, and C₁₋₆ aryl-C₁₋₆ alkyl.

[0017] R₄ is a straight-chain or branched C₁₋₂₀ alkyl saturated or unsaturated radical with one to three double and/or triple bonds, and which can be unsubstituted or optionally substituted on the same or different C atoms by one, two or more aryl, heteroaryl, halogen, C₁₋₆ alkoxy, amino, mono-C₁₋₄ alkylamino or di-C₁₋₄ alkylamino;

[0018] a phenyl ring or a naphthyl ring, which can be unsubstituted or mono- or polysubstituted by identical or different substituents from the group of straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, halogen, cyano, C₁₋₆ alkoxycarbonylamino, C₁₋₆ alkoxy, carboxyl, C₁₋₈ alkoxycarbonyl, straight-chain or branched C₁₋₆ alkyl which is substituted by one or more fluorine atoms, suitably trifluoromethyl, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, suitably methoxy or ethoxy, where adjacent oxygen atoms can also be linked by C₁₋₂ alkylene groups, suitably a methylene group, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, aryl, which can be unsubstituted or mono- or polysubstituted by identical or different substituents from the group of straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, carboxyl, straight-chain or branched C₁₋₈ alkoxycarbonyl, by trifluoromethyl, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, suitably methoxy or ethoxy, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, cyano, straight-chain or branched cyano-C₁₋₆ alkyl;

[0019] a 2-, 4-, 5- or 6-pyrimidinyl radical or 2-, 4-, 5- or a 6-pyrimidinyl-C₁₋₄ alkyl radical, where the C₁₋₄ alkyl radical is unsubstituted or is mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 4-, 5- or 6-pyrimidinyl radical is unsubstituted or mono- di- or trisubstituted by Y;

[0020] a 3-, 4-, 5- or 6-pyridazinyl radical or 3-, 4-, 5- or 6-pyridazinyl-C₁₋₄ alkyl radical, where the C₁₋₄ alkyl radical is unsubstituted or mono- or polysubstituted by identical or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 3-, 4-, 5- or 6-pyridazinyl radical is unsubstituted or is mono- di- or trisubstituted by Y;

[0021] a 2-, 3-, 5- or 6-pyrazinyl radical or 2-, 3-, 5- or 6-pyrazinyl-C₁₋₄ alkyl radical, where the C₁₋₄ alkyl radical is unsubstituted or mono- or polysubstituted by identical or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 3-, 5- or 6-pyrazinyl radical is unsubstituted or is mono- di- or trisubstituted by Y;

[0022] a 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl radical or 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl-C₁₋₄ alkyl radical, where the C₁₋₄ alkyl radical is unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl radical is unsubstituted or mono- or up to pentasubstituted by Y;

[0023] a 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl radical or 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl-C₁₋₄ alkyl radical, where the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of hydrogen, C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 3-, 5-, 6-, 7-, or 8-quinazolinyl radical can be unsubstituted or mono- or up to pentasubstituted by Y;

[0024] a 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl radical, or a 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl-C₁₋₄ alkyl radical, where the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl radical can be unsubstituted or mono- or up to pentasubstituted by Y;

[0025] a 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl radical or 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl-C₁₋₄ alkyl radical, where the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl radical can be unsubstituted or mono- or up to pentasubstituted by Y;

[0026] a 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl radical or 2-, 3-, 4-, 5-, 6-, 7 or 8-quinolyl-C₁₋₄ alkyl radical, where the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl radical can be unsubstituted or mono- or up to hexasubstituted by Y;

[0027] a 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl radical or 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl-C₁₋₄ alkyl radical, where the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl radical can be unsubstituted or mono- or up to hexasubstituted by identical or different substituents from the group of hydrogen, or Y;

[0028] a 2-, 6-, 8- or 9-[9H]-purinyl radical or a 2-, 6-, 8- or 9-[9H]-purinyl-(C₁-C₄)-alkyl radical, in which the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 6-, 8- or 9-[9H]-purinyl radical can be unsubstituted or mono- di- or trisubstituted by the same or different substituents of the group of hydrogen, or Y;

[0029] a 2-, 6-, 7- or 8-[7H]-purinyl radical or a 2-, 6-, 7- or 8-[7H]-purinyl-(C₁-C₄)-alkyl radical, in which the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 6-, 7- or 8-[7H]-purinyl radical can be unsubstituted or mono- to trisubstituted by the same or different substituents from the group of hydrogen, or Y;

[0030] a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl radical, or a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl-C₁₋₄ alkyl radical, where the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl radical can be unsubstituted or mono- or up to octasubstituted by the same or different substituents from the group of hydrogen, or Y;

[0031] a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl radical, or a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl-C₁₋₆ alkyl radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of hydrogen, C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl radical can be unsubstituted or mono- or up to octasubstituted by Y;

[0032] a 2-, 3-, 4-, 5- or 6-pyridyl radical in which the 2-, 3-, 4-, 5- or 6-pyridyl radical can be unsubstituted or mono- or up to tetrasubstituted by the same or different substituents from the group of hydrogen, or Y;

[0033] a 2-, 3-, 4-, 5- or 6-pyridinyl-(C₁-C₆)-alkyl radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 3-, 4-, 5- or 6-pyridinyl radical can be unsubstituted or mono- to tetrasubstituted by the same or different substituents from the group of hydrogen, or Y;

[0034] a 2-, 3-, 4- or 5-thienyl radical or 2-, 3-, 4- or 5-thienyl-C₁₋₆ alkyl radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 3-, 4- or 5-thienyl radical can be unsubstituted or mono- di- or trisubstituted by the same or different substituents from the group of hydrogen, or Y;

[0035] a 2-, 4-, or 5-thiazolyl radical or 2-, 4-, or a 5-thiazolyl-C₁₋₆ alkyl radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 4-, or 5-thiazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y;

[0036] a 3-, 4-, or 5-isothiazolyl radical, or a 3-, 4-, or 5-isothiazolyl-C₁₋₆ alkyl radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 3-, 4-, or 5-isothiazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y;

[0037] a 2-, 4-, 5-, 6-, or 7-benzothiazolyl radical, or a 2-, 4-, 5-, 6-, or 7-benzothiazolyl-C₁₋₆ alkyl radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 4-, 5-, 6-, or 7-benzothiazolyl radical can be unsubstituted or mono- or up to tetrasubstituted by the same or different substituents from the group of hydrogen, or Y;

[0038] a 1-, 2-, 4-, or 5-imidazolyl radical, or a 1-, 2-, 4-, or 5-imidazolyl-C₁₋₆ alkyl radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 2-, 4-, or 5-imidazolyl radical can be unsubstituted or mono- or up to trisubstituted by the same or different substituents from the group of hydrogen, or Y;

[0039] a 1-, 3-, 4-, or 5-pyrazolyl radical or 1-, 3-, 4-, or a 5-pyrazolyl-C₁₋₆ alkyl radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 3-, 4- or 5-pyrazolyl radical can be unsubstituted or mono- di- or trisubstituted by the same or different substituents from the group of hydrogen, or Y;

[0040] a 1-, 2-, 3-, 4-, or 5-pyrrolyl radical, or a 1-, 2-, 3-, 4-, or 5-pyrrolyl-(C₁-C₆)-alkyl radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 2-, 3-, 4- or 5-pyrrolyl radical can be unsubstituted or mono- or up to tetrasubstituted by the same or different substituents from the group of hydrogen, or Y;

[0041] a 1-, 3-, or 5-[1.2.4]-triazolyl radical, or a 1-, 3-, or 5-[1.2.4]-triazolyl-C₁₋₆ radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of hydrogen, C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 3-, or 5-[1.2.4]-triazolyl radical can be unsubstituted or mono- or disubstituted by Y;

[0042] a 1-, 4-, or 5-[1.2.3]-triazolyl radical, or a 1-, 4-, or 5-[1.2.3]-triazolyl-C₁₋₆ alkyl radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 4-, or 5-[1.2.3]-triazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y;

[0043] a 1- or 5-[1H]-tetrazolyl radical or 1-, or a 5-[1H]-tetrazolyl-C₁₋₆ alkyl radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, or 5-[1H]-tetrazolyl radical can be unsubstituted or substituted by hydrogen, or Y;

[0044] a 2- or 5-[2H]-tetrazolyl radical or 2- or a 5-[2H]-tetrazolyl-C₁₋₆ alkyl radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2- or 5-[2H]-tetrazolyl radical can be unsubstituted or substituted by hydrogen, or Y;

[0045] a 2-, 4-, or 6-[1.3.5]-triazinyl radical, or a 2-, 4-, or 6-[1.3.5]-triazinyl-C₁₋₆ alkyl radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of hydrogen, C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 4-, or 6-[1.3.5]-triazinyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y;

[0046] a 2-, 4-, or 5-oxazolyl radical, or a 2-, 4-, or 5-oxazolyl-C₁₋₆ alkyl radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 4-, or 5-oxazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y;

[0047] a 3-, 4-, or 5-isoxazolyl radical, or a 3-, 4-, or 5-isoxazolyl-C₁₋₆ alkyl radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 3-, 4-, or 5-isoxazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y;

[0048] a 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl radical, or a 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl-C₁₋₆ alkyl radical, in which the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl radical can be unsubstituted or mono- or up to hexasubstituted by the same or different substituents from the group of hydrogen, or Y, and the isomers, in particular tautomers, diastereomers and enantiomers, and the pharmaceutically acceptable salts, particularly acid addition salts, thereof.

[0049] According to a further embodiment, acridine derivatives of the formula (1) are provided in which R, R₁, R₂, R₃, X, Z, P, Q, n and m have the meanings given above and R₄ is phenyl which is unsubstituted or substituted by one or up to five the same or different C₁₋₆ alkoxy groups, in which adjacent oxygen atoms can also be linked by C₁₋₂ alkylene groups.

[0050] According to a further embodiment, acridine derivatives of the formula (1) are provided in which R, R₁, R₂, R₃, X, Z, P, Q, n and m have the meanings given above and R₄ is 3,5-dimethoxyphenyl.

[0051] According to a further embodiment, acridine derivatives of the formula (1) are provided in which R₄ has the meanings given above, R, R₁, R₂, R₃ each are a hydrogen atom, Z is an oxygen atom, and X is a nitrogen atom, P and Q each are two hydrogen atoms (i.e. —CH2—), m is zero and n is the integer 2.

[0052] According to a further embodiment, acridine derivatives of the formula (1) are provided in which R, R₁, R₂ and R₃ each are a hydrogen atom, Z is an oxygen atom, and X is a nitrogen atom, P and Q each are two hydrogen atoms (i.e. —CH2—), m is zero, n is 2, and R₄ is a 3,5-dimethoxyphenyl radical.

[0053] According to a yet further feature of the present invention, a process is provided for preparing acridine derivatives of formula (1) by reacting an acridine carboxylic acid of the formula (2) in which R, R1, R2, R3 have the meanings given above, Z is an oxygen or sulfur atom, and Y is a leaving group such as halogen, hydroxyl, C₁₋₆ alkoxy, suitably methoxy or ethoxy, —O-tosyl, —O-mesyl or imidazolyl,

[0054] with an amine of the formula (3) in which R4, P, Q, X, m and n are as defined above, in the optional presence of diluents and auxiliaries, to form the desired acridine derivatives.

[0055] Synthesis Route

[0056] The compounds of the formula 1 can be obtained according to reaction scheme 1:

[0057] The starting materials of formulae (2) and (3) are either commercially available or can be prepared by procedures known per se. The starting materials (2) and (3) are useful intermediates for preparing the acridine derivatives of the formula (1) according to the invention.

[0058] The solvents and auxiliaries that can be optionally used, and the reaction parameters to be used, such as reaction temperature and reaction time, are known to the person skilled in the art owing to his expert knowledge.

[0059] The acridine derivatives of the formula (1) according to the present invention are suitable as medicaments, in particular as antitumor agents, for treating mammals, in particular man, but also domestic animals such as horses, cattle, dogs, cats, rabbits, sheep, poultry and the like.

[0060] According to a further feature of the present invention, a method is provided for controlling tumors in mammals, in particular man, by administering at least one acridine derivative of formula (1) to a mammal patient an amount effective for the treatment of the tumor. The therapeutically effective dose of the acridine derivative according to the invention in question which is to be administered for the treatment depends inter alia on the nature and the stage of the oncosis, the age and the sex of the patient, the type of administration and the duration of the treatment. Administration can take place orally, rectally, buccally (for example sublingually), parenterally (for example subcutaneously, intramuscularly, intradermally or intravenously), topically or transdermally.

[0061] According to a further feature of the present invention, medicaments are provided for the treatment of tumors, which comprise, as active ingredient, at least one acridine derivative of formula (1), or a pharmaceutically acceptable salt thereof, suitably together with conventional pharmaceutically acceptable auxiliaries, additives and carriers. These can be solid, semisolid, liquid or aerosol preparations. Suitable solid preparations include, for example, capsules, powders, granules, tablets. Suitable semisolid preparations include, for example, ointments, creams, gels, pastes, suspensions, oil-in-water and water-in-oil emulsions. Suitable liquid preparations include, for example, sterile aqueous preparations for parenteral administration which are isotonic with the blood of the patient.

[0062] The invention is further illustrated in more detail by the following example without being restricted to the example.

1-(3,5-Dimethoxyphenyl)-4-(9-acridinyl-carbonyl)piperazine (D-43411)

[0063] 8 g (35.84 mmol) of acridine-9-carboxylic acid were charged to 300 ml of DMF with stirring. 5.79 g (57.34 mmol) of N-methylmorpholine, then a solution of 24.24 g (46.59 mmol) of Py-BOP (1-benzotriazolyltripyrrolidinophosphonium hexafluorophosphate) and 7.96 g (35.81 mmol) of 1-(3,5-dimethoxyphenyl)piperazine in 50 ml of DMF were added successively to the mixture with further stirring. The mixture was stirred at room temperature for 12 hours, the DMF was distilled off under reduced pressure and the residue was purified on a silica gel column (Kieselgel 60, from Merck AG, Darmstadt) using the mobile phase dichloromethane/methanol/ (95:5 v/v).

[0064] Yield: 12.9 (84.2% of theoretical) m.p.: 172-175° C.

[0065] 1. Antiproliferative Action in Various Tumor Cell Lines

[0066] In a proliferation test, the antiproliferative activity of the substance D-43411 was examined using established tumor cell lines. The Cellular Dehydrogenation activity is determined in the test, which enables determination of the vitality of the cell and, indirectly, the cell count. The cell lines used are the human cervical carcinoma cell lines KB/HeLa (ATCC/CCL17), the murine lymphocyte leukemia L1210 (ATCC CCL-219), the human breast adenocarcinoma line MCF7/ATCC HTB22) and the ovary adenocarcinoma line SKOV-3 (ATCC HTB77). These are established cell lines which are very well characterized and were obtained from ATCC and cultured.

[0067] The results shown in Table 1 demonstrate the highly potent antiproliferative action of D-43411 in the cell lines SKOV-3, L-1210 and HeLa/KB. Due to the particularly slow growth of the MCF7 line, the effect of D-43411 in the test period of 48 h is only small (18% inhibition at 3.16 mg/ml; thus stated as >3.16). TABLE 1 In-vitro cytotoxicity in tumor cell lines (values determined from 5 substance concentrations) XTT - Assay IC⁵⁰ [mg/ml] D M KB/He number Structure W SKOV-3 L1210 La MCF7 D- 429 <0.0003 <0.0003 <0.0003 >3.16 43411

[0068] 2. Method

[0069] XTT Test for Cellular Dehydrogenase Activity

[0070] The adherently growing tumor cell lines HeLa/KB, SKOV-3 and MCF7 and the L1210 leukemia line, which grows in suspension, were cultivated under standard conditions in an incubator with gas inlet at 37° C., 5% CO₂ and 95% atmospheric humidity. On Test Day 1, the adherent cells are detached using trypsine/EDTA and pelleted by centrifugation. The cell pellet is then resuspended in RPMI culture medium at the appropriate cell count and transferred to a 96-well microtitre plate. The plates are then overnight cultivated in the incubator with gas inlet. The test substances are made up as stock solutions in DMSO and, on Test Day 2, diluted with culture medium to the desired concentrations. The substances in the culture medium are then added to the cells and incubated in the incubator with gas inlet for 45 h. Cells which have not been treated with test substance serve as control.

[0071] 1 mg/ml of XTT (sodium 3′-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzenesulfonic acid) is dissolved for the XTT assay in RPMI-1640 medium without Phenol Red. Additionally, a 0.383 mg/ml solution is prepared of PMS (N-methyldibenzopyrazine methyl sulfate) in phosphate-buffered saline (PBS). On Test Day 4, 75 ml/well of the XTT-PMS mixture are pipetted onto the cell plates, which by now have been incubated with the test substances for 45 hours. To this end, the XTT solution is mixed with the PMS solution in a ratio of 50:1 (v/v) shortly before use. The cell plates are then incubated in the incubator with gas inlet for a further 3 hours, and the optical density (OD_(490nm)) is determined in a photometer.

[0072] Using the OD_(490nm) obtained, the inhibition is calculated in percent relative to the control. The antiproliferative activity is estimated using regression analysis.

EXAMPLE I

[0073] Tablet containing 50 mg of active compound Composition: (1) Active compound 50.0 mg (2) Lactose 98.0 mg (3) Maize starch 50.0 mg (4) Polyvinylpyrrolidone 15.0 mg (5) Magnesium stearate 2.0 mg Total: 215.0 mg

[0074] Preparation

[0075] Components (1), (2) and (3) are mixed and granulated with an aqueous solution of (4). The dried granules are admixed with (5). This mixture is tabletted.

EXAMPLE II

[0076] Capsule containing 50 mg of active compound Composition: (1) Active compound 50.0 mg (2) Maize starch, dried 58.0 mg (3) Lactose powder 50.0 mg (4) Magnesium stearate 2.0 mg Total: 160.0 mg

[0077] Preparation

[0078] (1) is ground with (3). This ground material is added with vigorous mixing to the mixture of (2) and (4). This powder mixture is, on a capsule filling machine, filled into hard gelatine capsules size 3. TABLE 9 New Acridinyl-Derivatives with antitumoral activity m/e Ex. R R₁ R₂ R₃ X Z n m P Q R₄ Code-Nr. (M + H) 1 H H H H N O 2 0 H₂ H₂ 43411 428 2 H H H H N O 2 0 H₂ H₂ 82266 394 3 H H H H N O 2 0 H₂ H₂ 81694 437 4 H H H H N O 2 0 H₂ H₂ 81745 396 5 H H H H N O 2 0 H₂ H₂ 81803 432 6 H H H H N O 2 0 H₂ H₂ 81804 384 7 H H H H N O 2 0 H₂ H₂ 81805 396

[0079] TABLE 10 New Acridinyl-Derivatives with antitumoral activity m/e Ex. R R₁ R₂ R₃ X Z n m P Q R₄ Code-Nr. (M + H)  8 H H H H N O 2 0 H₂ H₂ 81851 370  9 H H H H N O 2 0 H₂ H₂ 81854 405 10 H H H H N O 2 0 H₂ H₂ 81439 404 11 H H H H CH O 2 0 H₂ H₂ 81806 367 12 H H H H N O 2 0 H₂ H₂ 81852 428 HCl- Salz 13 H H H H N O 2 0 H₂ H₂ 82316 383 14 H H H H N O 2 0 H₂ H₂ 82317 396

[0080] TABLE 11 New Acridinyl-Derivatives with antitumoral activity m/e Ex. R R₁ R₂ R₃ X Z n m P Q R₄ Code-Nr. (M + H) 15 H H H H N O 2 0 H₂ H₂ 82318 398 16 H H H H N O 2 0 H₂ H₂ 82673 359 17 H H H H N O 2 0 H₂ H₂ 82747 400 

We claim:
 1. Acridine derivatives of the formula 1

wherein R, R₁, R₂, R₃ can be attached to any of the acridine carbon atoms C₁ to C₉, and are the same or different and independently of one another are hydrogen, hydroxyl, a straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, straight-chain or branched C₁₋₈ alkylcarbonyl, straight-chain or branched C₁₋₈ alkoxy, halogen, aryl-C₁₋₈ alkoxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, C₁₋₈ alkoxycarbonylamino, C₁₋₈ alkoxycarbonylamino-C₁₋₈ alkyl, cyano, straight-chain or branched cyano-C₁₋₆ alkyl, carboxyl, C₁₋₈ alkoxycarbonyl, C₁₋₄ alkyl which is substituted by one or more fluorine atoms, carboxy-C₁₋₈ alkyl or C₁₋₈ alkoxycarbonyl-C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, straight-chain or branched cyano-C₁₋₆ alkyl, aryl, where the aryl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of halogen, straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, carboxyl, straight-chain or branched C₁₋₈ alkoxycarbonyl, by trifluoromethyl, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, cyano, straight-chain or branched cyano-C₁₋₆ alkyl, Z is oxygen or sulfur, where the radical

substituted on the acridine heterocycle can be attached to any one of the C atoms C₁₋₉ of the acridine ring skeleton; P,Q are independently of one another oxygen or in each case two hydrogen atoms as in —CH₂—; X is nitrogen or C—R₅, where R₅ is hydrogen or C₁₋₆ alkyl groups; n,m independently of one another are a cardinal number between 0 and 3, with the proviso that when n is 0, X is a CR₅R₆ group where R₅ and R₆ independently of one another are hydrogen or C₁₋₆ alkyl and that the nitrogen atom adjacent to the C═Z group is substituted by a hydrogen atom or a C₁₋₆ alkyl group; R₄ is a straight-chain or branched (C₁₋₂₀)-alkyl radical which can be saturated or unsaturated, with one to three double and/or triple bonds, and which can be unsubstituted or can be substituted at the same or different C atoms by one, two or more of aryl, heteroaryl, halogen, cyano, —C═NH (NH₂), C₁₋₆ alkoxycarbonylamino, C₁₋₆ alkoxy, amino, mono-C₁₋₄ alkylamino or di-C₁₋₄ alkylamino; carboxy, C₁₋₄ alkoxycarbonyl, a C₆₋₁₄ aryl radical, C₆₋₁₄ aryl-C₁₋₄ alkyl radical or a C₂₋₁₀ heteroaryl or C₂₋₁₀ heteroaryl-C₁₋₄ alkyl radical which contains one or more heteroatoms N, O and S, where the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O) and where the C₆₋₁₄ aryl or C₂₋₁₀ heteroaryl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, halogen, cyano, C₁₋₆ alkoxycarbonylamino, C₁₋₆ alkoxy, carboxyl, C₁₋₈ alkoxycarbonyl, straight-chain or branched C₁₋₆ alkyl which is substituted by one or more fluorine atoms, hydroxyl, straight-chain or branched C₁₋₈-alkoxy, where adjacent oxygen atoms can also be linked by C₁₋₂ alkylene groups, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, aryl, which for its part can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, carboxyl, straight-chain or branched C₁₋₈ alkoxycarbonyl, by trifluoromethyl, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, cyano, straight-chain or branched cyano-C₁₋₆ alkyl; and their structural isomers and stereoisomers, particularly tautomers, diastereomers and enantiomers, and their pharmaceutically acceptable salts, particularly acid addition salts.
 2. The acridine derivative of claim 1, wherein in R, R₁, R₂, and R₃, said C₁₋₈ alkylcarbonyl is acetyl, said aryl-C₁₋₈ alkoxy is benzyloxy or phenylethoxy, said fluorine atoms is a trifluoromethyl group, said C₂₋₆ alkenyl is allyl, said C₂₋₆ alkynyl is ethynyl or propargyl, said cyano-C₁₋₆ alkyl is cyanomethyl, said C₁₋₈ alkoxycarbonyl is is butoxycarbonyl, and said C₁₋₈ alkoxy is methoxy or ethoxy. and in R₄ said fluorine atomes are trifluromethyl, said C₁₋₈ alkoxy is methoxy or ethoxy, and said C₁₋₂ alkylene is methylene.
 3. The acridine derivative of formula 1 of claim 1, wherein R, R1, R2, R3, X, Z, P, Q, n and m have the meanings therein, and Y is a substituent group of the same or different substituents of C₁₋₆ alkyl, halogen, nitro, amino, mono-C₁₋₆ alkylamino, di-C₁₋₆ alkylamino, hydroxyl, C₁₋₆ alkoxy, benzyloxy, carboxyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkoxycarbonylamino or C₁₋₆ alkyl mono- or polysubstituted with fluorine, C₁₋₆ aryl, or C₁₋₆ aryl-C₁₋₆ alkyl. R4 is a straight-chain or branched C₁₋₂₀ alkyl radical which can be saturated or unsaturated, with one to three double and/or triple bonds, and which can be unsubstituted or optionally substituted on the same or different C atoms by one, two or more aryl, heteroaryl, halogen, C₁₋₆ alkoxy, amino, mono-C₁₋₄ alkylamino or di-C₁₋₄ alkylamino; a phenyl ring or a naphthyl ring, each of which can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, halogen, cyano, C₁₋₆ alkoxycarbonylamino, C₁₋₆ alkoxy, carboxyl, C₁₋₈ alkoxycarbonyl, straight-chain or branched C₁₋₆ alkyl which is substituted by one or more fluorine atoms, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, aryl, which can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of straight-chain or branched C₁₋₈ alkyl, C₃₋₇ cycloalkyl, carboxyl, straight-chain or branched C₁₋₈ alkoxycarbonyl, by trifluoromethyl, hydroxyl, straight-chain or branched C₁₋₈ alkoxy, benzyloxy, nitro, amino, mono-C₁₋₄ alkylamino, di-C₁₋₄ alkylamino, cyano, straight-chain or branched cyano-C₁₋₆ alkyl; a 2-, 4-, 5- or 6-pyrimidinyl radical, or a 2-, 4-, 5- or 6-pyrimidinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 4-, 5- or 6-pyrimidinyl radical can be unsubstituted or mono- to trisubstituted by the same or different substituents from the group of hydrogen, or Y; a 3-, 4-, 5- or 6-pyridazinyl radical, or a 3-, 4-, 5- or 6-pyridazinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 3-, 4-, 5-, or the 6-pyridazinyl radical can be unsubstituted or mono- to trisubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 3-, 5- or 6-pyrazinyl radical, or a 2-, 3-, 5- or 6-pyrazinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 3-, 5- or 6-pyrazinyl radical can be unsubstituted or mono- or up to trisubstituted by the same or different substituents from the group of hydrogen, or Y; a 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl radical, or a 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 3-, 4-, 5-, 6-, 7-, or 8-cinnolinyl radical can be unsubstituted or mono- or up to pentasubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl radical, or a 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of hydrogen, C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 4-, 5-, 6-, 7-, or 8-quinazolinyl radical can be unsubstituted or mono- or up to pentasubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl radical, or a 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 3-, 5-, 6-, 7-, or 8-quinoxalinyl radical can be unsubstituted or mono- or up to pentasubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl radical or a 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 4-, 5-, 6-, 7-, or 8-phthalazinyl radical can be unsubstituted or mono- or up to pentasubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl radical, or a 2-, 3-, 4-, 5-, 6-, 7 or 8-quinolyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl radical can be unsubstituted or mono- or up to hexasubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl radical, or a 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl radical can be unsubstituted or mono- to hexasubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 6-, 8- or 9-[9H]-purinyl radical, or a 2-, 6-, 8- or 9-[9H]-purinyl C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 6-, 8- or 9-[9H]-purinyl radical can be unsubstituted or mono- to trisubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 6-, 7- or 8-[7H]-purinyl radical, or a 2-, 6-, 7- or 8-[7H]-purinyl-C₁₋₄ alkyl radical, wherein the C₁₋₄ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 6-, 7- or 8-[7H]-purinyl radical can be unsubstituted or mono- or up to trisubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl radical, or a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl-C₁₋₄ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-acridinyl radical can be unsubstituted or mono- or up to octasubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl radical, or a 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of hydrogen, C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8- or 9-phenanthridinyl radical can be unsubstituted or mono- or up to octasubstituted by Y; a 2-, 3-, 4-, 5- or 6-pyridyl radical wherein the 2-, 3-, 4-, 5- or 6-pyridinyl radical can be unsubstituted or mono- or up to tetrasubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 3-, 4-, 5-, or a 6-pyridyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 3-, 4-, 5- or 6-pyridinyl radical can be unsubstituted or mono- or up to tetrasubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 3-, 4- or 5-thienyl radical, or a 2-, 3-, 4- or 5-thienyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 3-, 4- or 5-thienyl radical can be unsubstituted or mono- to trisubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 4-, or 5-thiazolyl radical or 2-, 4-, or a 5-thiazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 4-, or 5-thiazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y; a 3-, 4-, or 5-isothiazolyl radical, or a 3-, 4-, or 5-isothiazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 3-, 4-, or 5-isothiazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 4-, 5-, 6-, or 7-benzothiazolyl radical, or a 2-, 4-, 5-, 6-, or 7-benzothiazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 4-, 5-, 6-, or 7-benzothiazolyl radical can be unsubstituted or mono- to tetrasubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 2-, 4-, or 5-imidazolyl radical or 1-, 2-, 4-, or a 5-imidazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 2-, 4-, or 5-imidazolyl radical can be unsubstituted or mono- or up to trisubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 3-, 4-, or 5-pyrazolyl radical, or a 1-, 3-, 4- or 5-pyrazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 3-, 4- or 5-pyrazolyl radical can be unsubstituted or mono- to trisubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 2-, 3-, 4-, or 5-pyrrolyl radical, or a 1-, 2-, 3-, 4-, or 5-pyrrolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 2-, 3-, 4- or 5-pyrrolyl radical can be unsubstituted or mono- to tetrasubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 3-, or 5-[1.2.4]-triazolyl radical or 1-, 3-, or a 5-[1.2.4]-triazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of hydrogen, C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 3-, or 5-[1.2.4]-triazolyl radical can be unsubstituted or mono- or disubstituted by Y; a 1-, 4-, or 5-[1.2.3]-triazolyl radical or 1-, 4-, or 5-[1.2.3]-triazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 4-, or 5-[1.2.3]-triazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y; a 1- or 5-[1H]-tetrazolyl radical, or a 1-, or 5-[1H]-tetrazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of (C₁-C₆)-alkyl, halogen or oxo (═O), and the 1-, or 5-[1H]-tetrazolyl radical can be unsubstituted or substituted by hydrogen, or Y; a 2- or 5-[2H]-tetrazolyl radical, or a 2- or 5-[2H]-tetrazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2- or 5-[2H]-tetrazolyl radical can be unsubstituted or substituted by hydrogen, or Y; a 2-, 4-, or 6-[1.3.5]-triazinyl radical, or a 2-, 4-, or 6-[1.3.5]-triazinyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of hydrogen, C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 4-, or 6-[1.3.5]-triazinyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y; a 2-, 4-, or 5-oxazolyl radical, or a 2-, 4-, or 5-oxazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 2-, 4-, or 5-oxazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y; a 3-, 4-, or 5-isoxazolyl radical, or a 3-, 4-, or 5-isoxazolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 3-, 4-, or 5-isoxazolyl radical can be unsubstituted or mono- or disubstituted by the same or different substituents from the group of hydrogen, or Y; a 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl radical, or a 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl-C₁₋₆ alkyl radical, wherein the C₁₋₆ alkyl radical can be unsubstituted or mono- or polysubstituted by the same or different substituents from the group of C₁₋₆ alkyl, halogen or oxo (═O), and the 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl radical can be unsubstituted or mono- to hexasubstituted by the same or different substituents from the group of hydrogen, or Y.
 4. The acridine derivative of claim 3, wherein in Y said C₁₋₆ alkyl polysubstituted with fluorine is trifluoromethyl.
 5. The acridine derivative of claim 1, wherein R, R₁, R₂, R₃, X, Z, P, Q, n and m have the meanings given above and R4 is phenyl which is unsubstituted or substituted by one or up to five the same or different C₁₋₆ alkoxy groups, wherein adjacent oxygen atoms can also be linked by C₁₋₂ alkylene groups.
 6. The acridine derivative of claim 1, wherein R, R₁, R₂, R₃, P, Q, X, Z, n and m have the meanings given above, and R₄ is 3,5-dimethoxyphenyl.
 7. The acridine derivative of claims 1 or 3, wherein R₄ has the meanings given above, R, R₁, R₂, R₃ each are a hydrogen atom, Z represents an oxygen atom, X is a nitrogen atom, P and Q each are two hydrogen atoms as in —CH2—, m is zero, and n is
 2. 8. The acridine derivative of claim 1, wherein R, R₁, R₂, R₃ each are a hydrogen atom, Z is an oxygen atom, X is a nitrogen atom, P and Q are each two hydrogen atoms as in —CH2—, m is zero, n is 2, and R₄ is 3,5-dimethoxyphenyl.
 9. A process for preparing the acridine derivative of claim 1 which comprises reacting an acridine carboxylic acid of formula (2)

wherein R, R1, R2, R3 have the meanings given above, Z is an oxygen or sulfur atom, and Y is a leaving group.
 10. The method of claim 9, wherein said leaving group is such as halogen, hydroxyl, C₁₋₆ alkoxy, preferably methoxy or ethoxy, —O-tosyl, —O-mesyl or imidazolyl, with an amine of formula (3)

wherein R₄, X, P, Q, m and n have the meanings given above, and optionally in the presence of if appropriate using diluents and auxiliaries.
 11. A method for treating tumors in mammals, which comprises administering to said mammal an antitumor effective amount of at least one acridine derivative any of claims 1 or
 3. 12. A drug which comprises as active ingredient, at least one acridine derivative of claims 1 or
 3. 13. The pharmaceutically acceptable acid salt of the acridine derivative of claim 1, when formed with one of the acids hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, acetic acid, tartaric acid, malic acid, malonic acid, embonic acid, trifluoroacetic acid maleic acid, methonesulfuric acid, or sulfo acetic acid. 